• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Eyevensys

Eyevensys raises $12M for its gene therapy ocular drug delivery platform

August 4, 2021 By Sean Whooley

Eyevensys

Eyevensys, a developer of gene therapies for ophthalmic diseases, announced today that it raised $12 million in a Series B plus funding round. The funding, led by Korea Investment Partners, also includes existing investors who will join the round and support the accelerated development of Eyevensys’ EYS809 program for treating wet age-related macular degeneration (AMD) […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Optical/Ophthalmic Tagged With: Eyevensys

Ocular continues personnel shakeup with new CMO | Personnel Moves – Sept. 13, 2017

September 14, 2017 By Sarah Faulkner

Ocular Therapeutix

After Ocular Therapeutix‘s (NSDQ:OCUL) founder & CEO, Amar Swahney, stepped down earlier this year, pharma executive Antony Mattessich stepped in to assume the corner office. He signaled some major changes to the company’s business strategy in a call with analysts last month, including an attempt to ‘aggressively seek new partnerships’ and ‘enhance [the company’s] credibility’. As […]

Filed Under: Drug-Device Combinations, Featured, Personnel, Pharmaceuticals, Wall Street Beat Tagged With: Aeterna Zentaris, Bayer AG, Biogen Idec, Eyevensys, lyndra, Mylan, Ocular Therapeutix, Proteus Digital Health, rebiotix, Teva

First uveitis patient treated with Eyevensys’ electro-transfection system

May 9, 2017 By Sarah Faulkner

Eyevensys

Private biotech Eyevensys said today that it treated the 1st patient in a first-in-human phase I/II trial of its lead candidate, EYS606, for the treatment of non-infectious uveitis. The patient was treated in Paris at the Cochin Institute using the company’s EyeCET technology. The EyeCET platform is an electro-transfection injection system that delivers non-viral plasmids to encode […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Optical/Ophthalmic Tagged With: Eyevensys

Eyevensys wins approval to start clinical development of EyeCET platform

April 20, 2017 By Sarah Faulkner

Eyevensys

Private biotech Eyevensys said today that it won approval from the UK Medicines and Healthcare Products Regulatory Agency to advance its EyeCET platform into clinical development. The company’s EyeCET platform uses an electro-transfection injection system to deliver non-viral plasmids that encode for disease-specific therapeutic proteins in the ciliary muscle of the eye. Eyevensys’ lead product […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Optical/Ophthalmic, Wall Street Beat Tagged With: Eyevensys

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS